- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02053675
Hemodynamic Effects of Vasopressin in Early Septic Shock Stage
Hemodynamic Effects of Low Doses of Arginine Vasopressin in Early Septic Shock Stage
Study Overview
Detailed Description
Immediately before vasopressin infusion, fluid responsiveness was evaluated by delta PP (ΔPP) with ΔPP module attached to the monitor (DX 20x20, Dixtal, São Paulo, Brazil). Continuous sedation was maintained to control spontaneous ventilatory efforts. ΔPP > 13% receive crystalloid (Ringer's lactate or normal saline 0.9%) challenges until the ΔPP were below this value. Patients in whom was not possible to measure ΔPP, received crystalloid aliquots of 500 ml until there was no increase in cardiac output greater than 10%. Vasopressors were used to maintain mean arterial pressure above 65 mmHg. The fraction of inspired oxygen was adjusted to maintain oxygen saturation between 92-94%.
Thirty minutes after initial stabilization (the pre-vasopressin), all hemodynamic and respiratory measurements were obtained (pre-vasopressin), namely mean arterial pressure (MAP), heart rate (HR), right atrial pressure (RAP) , mean pulmonary artery pressure (MPAP), occluded pulmonary artery pressure (OPAP), cardiac index (CI), stroke index (SI), systemic vascular resistance index (SVRI), pulmonary vascular resistance index (PVRI). Samples were collected for blood gas analysis and arterial and mixed venous blood lactate.
Direct analysis of the sublingual microcirculation was done at that time by videomicroscopy obtained by SDF (Microscan; MicroVision Medical, Amsterdam, Netherlands), following the protocol previously described. Briefly, after removal of secretions, the lens of SDF was placed in the sublingual space without exerting any pressure. All images were obtained by a qualified physician using the recommended techniques to ensure image quality. We obtained three sequential images of high quality stable for at least 20 seconds, of both sides of the tongue while avoiding artifacts pressure. All images were captured using a notebook and a video converter analog / digital (ADVC110, Canopus Co, San Jose, California).
After obtaining baseline data, vasopressin was infused at fixed dose of 0.04 U / min. After one hour of vasopressin(post-vasopressin), the same variables were collected. If required, the adrenergic vasopressors infusion was adjusted during the study to maintain the target MAP from 65 to 70 mmHg. If patients were receiving dobutamine, its dose was kept constant during the study procedures. If fluid replacement or adjustment of ventilatory parameters or sedation were needed during the study, the patient was excluded.
All images were subsequently analyzed using the AVA 3.0 ® software (Microvision Medical, Amsterdam, Netherlands), considering only vessels with a diameter less than 20 micrometers. A blinded investigator analyzed all the images in a random order. The microcirculatory flow index (MFI), the total vascular density (TVD), the proportion of perfused vessels (PPV), the perfused vessel density (PVD), and the heterogeneity index (HI) were calculated.
Briefly, the MFI is calculated from the imaginary division of the image captured and stabilized into four quadrants. Its calculation is the average of the subjective evaluation of the flow in the four quadrants, quantified 0-3, where 0 corresponds to absent flow, 1 intermittent flow, 2 and 3 sluggish flow and continuous flow, respectively. TVD is calculated from the assumption that it is proportional to the number of vessels crossing three horizontal lines and three vertical equidistant arbitrary placed in the overlay image. The program computes the number of vessels crossing the lines and vessels and the total is divided by the lines length. Perfusion subjective evaluation was done in each vessel, graduated from 0 to 3 (absent, intermittent, sluggish or continuous). The PPV is calculated from the total number of vessels counted in the TVD subtracted not perfused vessels (those with flow 0 or flow 1), according to the formula: PPV = TVD - not perfused vessels / TVD x100. The PVD is obtained by multiplying TVD and PPV. The HI is calculated from the difference between the highest and lowest MFI found in three images captured in each moment (before and after vasopressin), according to the formula: HI = highest MFI - lowest MFI / MFI average.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
São Paulo/SP
-
São Paulo, São Paulo/SP, Brazil, 04024900
- Hospital São Paulo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients over 18 years
- Septic shock using adrenergic vasopressors for less than 48 hours
- Arterial catheter and pulmonary artery catheter with semi measurement of cardiac output by thermodilution (Vigilance, Edwards Lifesciences, Irvine, CA, USA) inserted
- Signed consent declaration
Exclusion Criteria:
- Acute coronary disease
- Suspected or confirmed acute mesenteric ischemia
- Severe hyponatremia (Na + <130 mmol / L)
- Raynaud's phenomenon
- Sclerodermia
- Pregnancy
- Technical difficulties to capture videomicroscopy with sublingual SDF
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Vasopressin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The primary objective of this study was to evaluate the effect of vasopressin infusion in microcirculation of septic shock patients
Time Frame: one hour after vasopressin initiation
|
Significant changes in microcirculatory parameters - MFI (absolute number), TVD (mm/mm2), PVD (mm/mm2), PPV (%), HI (%)
|
one hour after vasopressin initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The secondary objectives were to evaluate the effects of vasopressin on macrocirculation, and correlate potential microcirculatory effects related to its use, with baseline systemic circulation and microcirculation.
Time Frame: one hour after vasopressin initiation
|
Significant changes in HR (bpm), CI (L/min.m2),
SI (ml/beat/m2), oxigen delivery (ml/min), lactate (mg/dL), CO2 gradient (mmHg), and correlation between these changes and potential microcirculatory parameters alteration (MFI, TVD, PVD, PPV, HI)
|
one hour after vasopressin initiation
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Vasopress FAPESP 2010/50096-6
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
Laiba QamarRecruitingSeptic Shock | Fluid Refractory Septic ShockPakistan
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Artcline GmbHRecruitingSepsis | Septic Shock | Immunoparalysis in Septic ShockGermany
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityCompleted
Clinical Trials on Vasopressin infusion
-
University of AlbertaTerminatedPulmonary HypertensionCanada
-
Azienda Usl di BolognaRecruitingSeptic Shock | Renal Function ReplacementItaly
-
University of Roma La SapienzaCompleted
-
University of AarhusFerring PharmaceuticalsCompletedNocturnal Enuresis | Nocturia | Gender Difference in V2 Receptor Function in Response to dDAVP InfusionDenmark
-
Seoul National University HospitalCHA UniversityCompletedComparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy (VALENTINE)Uterine LeiomyomaKorea, Republic of
-
Columbia UniversityCompletedHypertension | End Stage Renal DiseaseUnited States
-
Hospital Nossa Senhora da ConceicaoRecruiting
-
University of Sao PauloHospital Universitário Cassiano Antônio de Moraes/HUCAM; Hospital Santa Casa...RecruitingVasoplegic Syndrome of Cardiac SurgeryBrazil
-
Medical University of BialystokRecruiting
-
Osaka UniversityOsaka City UniversityCompleted